Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F13%3A10209592" target="_blank" >RIV/00064203:_____/13:10209592 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/13:10209592
Výsledek na webu
<a href="http://dx.doi.org/10.1182/blood-2013-02-484097" target="_blank" >http://dx.doi.org/10.1182/blood-2013-02-484097</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood-2013-02-484097" target="_blank" >10.1182/blood-2013-02-484097</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004
Popis výsledku v původním jazyce
Outcomes of patients with acute myeloid leukemia (AML) improve significantly by intensification of induction. To further intensify anthracycline dosage without increasing cardiotoxicity, we compared potentially less cardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a higher-than-equivalent dose (80 vs 12 mg/m(2) per day for 3 days) during induction. In the multicenter therapy-optimization trial AML-BFM 2004, 521 of 611 pediatric patients (85%) were randomly assigned to L-DNR or idarubicin induction. Five-year results in both treatment arms were similar (overall survival 76% +/- 3% [L-DNR] vs 75% +/- 3% [idarubicin], P-logrank = .65; event-free survival [EFS] 59% +/- 3% vs 53% +/- 3%, P-logrank = .25; cumulative incidence of relapse 29% +/- 3%vs 31% +/- 3%, P-(Gray) = .75), as were EFS results for standard (72% +/- 5% vs 68% +/- 5%, P-logrank = .47) and high-risk (51% +/- 4% vs 46% +/- 4%, P-logrank = .45) patients. L-DNR resulted in significantly better probability of EFS in
Název v anglickém jazyce
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004
Popis výsledku anglicky
Outcomes of patients with acute myeloid leukemia (AML) improve significantly by intensification of induction. To further intensify anthracycline dosage without increasing cardiotoxicity, we compared potentially less cardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a higher-than-equivalent dose (80 vs 12 mg/m(2) per day for 3 days) during induction. In the multicenter therapy-optimization trial AML-BFM 2004, 521 of 611 pediatric patients (85%) were randomly assigned to L-DNR or idarubicin induction. Five-year results in both treatment arms were similar (overall survival 76% +/- 3% [L-DNR] vs 75% +/- 3% [idarubicin], P-logrank = .65; event-free survival [EFS] 59% +/- 3% vs 53% +/- 3%, P-logrank = .25; cumulative incidence of relapse 29% +/- 3%vs 31% +/- 3%, P-(Gray) = .75), as were EFS results for standard (72% +/- 5% vs 68% +/- 5%, P-logrank = .47) and high-risk (51% +/- 4% vs 46% +/- 4%, P-logrank = .45) patients. L-DNR resulted in significantly better probability of EFS in
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Blood
ISSN
0006-4971
e-ISSN
—
Svazek periodika
122
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
7
Strana od-do
37-43
Kód UT WoS článku
000321909300009
EID výsledku v databázi Scopus
—